Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

• Published in: Journal of neuroimmunology Vol. 361; p. 577746
• Main Authors: Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Dolev, Mark, Menascu, Shay, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Sonis, Polina, Zilkha-Falb, Rina, Gurevich, Michael
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.12.2021
• Subjects: Adult; Antibodies, Viral - blood; Antirheumatic Agents - therapeutic use; BNT162 Vaccine - immunology; COVID-19; COVID-19 - prevention & control; Cross-Sectional Studies; Disease modifying treatments; Female; Humans; Humoral immunity; IgG antibody; Immunity, Humoral - immunology; Immunoglobulin G - blood; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - immunology; Prospective Studies; SARS-CoV-2; Vaccination; COVID-19; Multiple sclerosis; IgG antibody; Disease modifying treatments; Vaccination; Humoral immunity

Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and...